Study details
Enrolling now
A Trial Using 18F-FS PG PET
M.D. Anderson Cancer Center
NCT IDNCT07116486ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
60
Study length
about 6.6 years
Ages
18+
Locations
1 site in TX
What this study is about
This trial is testing if a special type of PET scan, using the radiopharmaceutical 18F-FSPG, can help guide treatment for liver cancer. The goal is to see how well this test works in people with liver cancer who are receiving Y90 radioembolization therapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Radiopharmaceutical 18F-FSPG
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Safety and Adverse Events (AEs)